Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
In a recent filing with the Securities and Exchange Commission, Baker Bros. Advisors LP, along with several associated entities, disclosed significant stock transactions involving Immunocore Holdings plc (NASDAQ:IMCR). The transactions, dated March 17, 2025, revealed a series of acquisitions totaling $23.99 million in American Depositary Shares (ADS) of the company. The shares were purchased at prices ranging from $29.5603 to $29.7416. The timing is notable as the stock, currently trading at $28.70, sits near its 52-week low of $27.19, with analysts setting price targets ranging from $23.45 to $100.
In addition to the purchases, the filing also noted the disposition of 2.5% Convertible Senior Notes due 2030, with a total value of $137.24 million. These transactions illustrate the ongoing investment activities of Baker Bros. Advisors LP in Immunocore Holdings, a company engaged in developing biological products. The company maintains strong liquidity with a current ratio of 4.38 and demonstrated robust revenue growth of 24.37% in the last twelve months. InvestingPro analysis reveals 7 additional key insights about IMCR’s financial health and valuation, available in the comprehensive Pro Research Report.
In other recent news, Immunocore Holdings reported its fourth-quarter 2024 earnings, revealing a significant miss on earnings per share (EPS) compared to analysts’ expectations. The company posted an EPS of -0.47, falling short of the forecasted -0.24, and revenue came in slightly below expectations at $84.05 million against the anticipated $84.53 million. Meanwhile, Immunocore has amended the indenture for its 2.50% Convertible Senior Notes due 2030 and filed a prospectus supplement for the resale of up to $150 million of these notes. In clinical developments, the company presented promising initial data from its ongoing Phase 1/2 STRIVE trial of IMC-M113V, a potential functional cure for HIV, at the Conference on Retroviruses and Opportunistic Infections 2025. The trial indicated that IMC-M113V was well tolerated and demonstrated a dose-dependent reduction in the HIV active reservoir and viral control in some patients after pausing antiretroviral treatment. Analyst firms H.C. Wainwright and BTIG have maintained their Buy ratings on Immunocore, with price targets of $100.00 and $91.00, respectively, following these announcements. Immunocore’s ongoing research and development efforts continue to garner attention as the company progresses with dose escalation at higher levels and anticipates releasing additional data in the next 12 to 18 months.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.